Title
Category
Credits
Event date
Cost
Myelodysplastic Syndromes: Treatment Updates and Emerging Data
  • Myelodysplastic Syndromes
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The management of myelodysplastic syndromes (MDS) is complicated by the generally advanced age of the patients. The major clinical problems are morbidities caused by cytopenias and the potential for MDS to progress to acute myeloid leukemia. There are limited treatment options following disease progression, particularly for patients with disease refractory to hypomethylating agents. As new data emerge, it is important for clinicians to be aware of all the treatment options available so they can devise individualized therapeutic strategies and improve clinical outcomes.
NCCN Guidelines® Insights - Myelodysplastic Syndromes, Version 2.2025
  • Myelodysplastic Syndromes
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.